EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Multizentrische StudieOpen Access

Phase 1 clinical trial of the ataxia telangiectasia and Rad3‐related inhibitor berzosertib with irinotecan in patients with advanced solid tumors (ETCTN 9938)

Liza C Villaruz iD, Jingxiao Jin, Hong Wang, James J Lee, Jason J Luke, John C Rhee, Saiama N Waqar, Geoffrey I Shapiro, James Cleary iD, Diwakar Davar, Timothy F Burns iD, Rashmi Verma und 24 weitere

Cancer · 2025

DOI: 10.1002/cncr.70157 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Cancer, 2025. Verfasst von Liza C Villaruz und 35 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Ataxia Telangiectasia Mutated Proteins, Irinotecan, Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Ataxia telangiectasia and Rad3‐related (ATR) inhibition with berzosertib potentiates the efficacy of irinotecan in preclinical models. The authors hypothesize that this combination is well tolerated, modulates the DNA damage response to irinotecan, and is associated with clinical activity in advanced solid tumors.

Methods

In this phase 1 study (NCT02595931), berzosertib 60–270 mg/m 2 was administered with irinotecan 180 mg/m 2 every 2 weeks in a 4‐week cycle. The primary end point was determination of the maximum tolerated dose and recommended phase 2 dose (RP2D). Antitumor activity, pharmacokinetics, and pharmacodynamics were secondary end points.

Results

Sixty‐three patients were enrolled, the majority with colorectal cancer (49%) or pancreatic cancer (21%). Median number of prior lines of therapy was four (range, 2–7). Two dose‐limiting toxicities, both febrile neutropenia, occurred among 45 patients treated with berzosertib 270 mg/m 2 and irinotecan 180 mg/m 2 . The most common treatment‐related grade ≥3 toxicities were lymphopenia (30%), neutropenia (29%), and anemia (25%). Two partial responses occurred in patients with pancreatic cancer and ataxia telangiectasia mutated (ATM) alterations: 32% decrease in an ATM E11828/ATM K1109* tumor lasting 15.8 months and 57% decrease in an ATM R3008H/germline ATM R1882* tumor lasting 13.6 months. Induction of DNA damage markers γH2AX and pNBS1 was observed in one tumor biopsy obtained post berzosertib and irinotecan combination treatment compared with post irinotecan alone.

Conclusion

Berzosertib 270 mg/m 2 and irinotecan 180 mg/m 2 was the RP2D. The combination is associated with manageable side effects and promising disease activity in ATM mutant solid tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsAtaxia Telangiectasia Mutated ProteinsIrinotecanNeoplasmsPyrazolesQuinazolinesAdultAgedFemaleHumansMaleMiddle AgedAtaxia TelangiectasiaDNA DamageMaximum Tolerated DosePancreatic NeoplasmsIsoxazolesPyrazines

Stichwörter der Autor:innen

ATR inhibitionberzosertibirinotecanphase 1solid tumors

Substanzen

Ataxia Telangiectasia Mutated ProteinsATR protein, humanberzosertibIrinotecanPyrazolesQuinazolinesIsoxazolesPyrazines

Autor:innen und Institutionen

  • Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
  • Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Department of Biostatistics, School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Washington University School of Medicine, St. Louis, Missouri, USA.
  • Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • UC Davis Comprehensive Cancer Center, Sacramento, California, USA.

ORCID-Profile: Liza C Villaruz, James Cleary, Timothy F Burns, Elizabeth J Davis, Joshua Deppas, Michael Suchko

Förderung

  • NCI NIH HHS

Zitieren

APA

Villaruz, L. C., Jin, J., Wang, H., Lee, J. J., Luke, J. J., Rhee, J. C., Waqar, S. N., Shapiro, G. I., Cleary, J., Davar, D., Burns, T. F., Verma, R., Amin, M., Appleman, L., Ciombor, K. K., Davis, E. J., Riess, J. W., Dees, E. C., Kim, E. J., …, & Beumer, J. H. (2025). Phase 1 clinical trial of the ataxia telangiectasia and Rad3‐related inhibitor berzosertib with irinotecan in patients with advanced solid tumors (ETCTN 9938). Cancer. https://doi.org/10.1002/cncr.70157

Vancouver

Villaruz LC, Jin J, Wang H, Lee JJ, Luke JJ, Rhee JC, et al. Phase 1 clinical trial of the ataxia telangiectasia and Rad3‐related inhibitor berzosertib with irinotecan in patients with advanced solid tumors (ETCTN 9938). Cancer. 2025. doi:10.1002/cncr.70157

BibTeX
@article{Villaruz2025,
  author = {Villaruz, Liza C and Jin, Jingxiao and Wang, Hong and Lee, James J and Luke, Jason J and Rhee, John C and Waqar, Saiama N and Shapiro, Geoffrey I and Cleary, James and Davar, Diwakar and Burns, Timothy F and Verma, Rashmi and Amin, Manik and Appleman, Leonard and Ciombor, Kristen K and Davis, Elizabeth J and Riess, Jonathan W and Dees, E Claire and Kim, Edward J and Cardin, Dana and Guo, Jianxia and Christner, Susan M and Deppas, Joshua and Parise, Angelina M and Schmitz, John C and Guerrouahen, Bella S and Suchko, Michael and Contreras, Alejandro and Li, Li and Ferry-Galow, Katherine V and Chang, Ting-Chia and Jiwani, Shahanawaz and Bakkenist, Christopher J and Chu, Edward and Gore, Steven D and Beumer, Jan H},
  title = {Phase 1 clinical trial of the ataxia telangiectasia and Rad3‐related inhibitor berzosertib with irinotecan in patients with advanced solid tumors (ETCTN 9938)},
  journal = {Cancer},
  year = {2025},
  doi = {10.1002/cncr.70157}
}
Kostenlos starten →